Data for ST000107   

(Analysis AN000177): Average values per metabolite and experimental factor (Units:nM)

Metabolite structureAll dataF1F2F3F4F5F6F7F8F9F10F11F12F13F14F15
1-Arachidonoyl Glycerol
13.91 9.48 17.02 15.24 17.10 13.37 7.29 9.73 6.85 6.90 17.52 9.92 21.20 10.45 9.77
1-Linoleoyl Glycerol
2.24 1.06 2.03 3.27 2.14 5.34 4.33 5.91 5.15 3.00 1.40 1.98 1.60 2.69 3.08
1-Oleoyl Glycerol
70.74 27.72 82.64 125.26 73.25 138.79 91.91 92.07 56.96 66.88 59.10 59.96 67.08 70.46 130.38
2-Arachidonoyl Glycerol
18.94 28.50 24.20 22.23 37.73 17.14 8.75 8.83 7.72 6.43 57.96 26.99 88.44 31.04 15.60
2-Linoleoyl Glycerol
14.63 13.28 10.04 22.68 18.40 35.40 11.93 13.57 13.40 9.37 9.09 7.53 7.51 9.39 29.87
2-Oleoyl Glycerol
60.84 56.64 50.80 104.25 93.58 198.38 59.23 70.72 64.56 50.18 66.80 75.74 70.98 78.58 244.38
a-Linolenoyl Ethanolamide
0.06 0.05 0.05 0.04 0.04 0.08 0.04 0.04 0.04 0.04 0.06 0.05 0.06 0.03 0.05
Arachidonoyl Ethanolamide
1.80 1.38 1.71 1.14 0.60 1.79 1.44 1.38 1.37 1.28 1.03 1.11 1.11 0.92 1.86
Dihomo-g-Linolenoyl Ethanolamide
0.25 0.24 0.36 0.26 0.18 0.31 0.21 0.19 0.20 0.19 0.30 0.25 0.20 0.21 0.34
Docosahexaenoyl Ethanolamide
3.09 3.06 3.09 2.82 4.18 2.99 2.21 2.41 2.32 2.18 4.21 4.82 5.33 5.09 3.40
Docosatetraenoyl Ethanolamide
0.63 0.32 0.63 0.44 0.27 0.98 0.59 0.53 0.44 0.54 0.75 0.89 0.60 0.67 1.22
Linoleoyl Ethanolamide
0.87 0.80 0.88 0.67 0.72 1.08 0.88 0.90 0.81 0.81 1.11 1.20 1.27 1.05 0.99
Oleoyl Ethanolamide
28.88 22.74 30.87 24.44 16.05 33.98 24.07 24.15 19.84 24.51 25.54 27.18 25.68 21.90 38.45
Palmitoyl Ethanolamide
14.82 14.66 15.60 14.17 12.32 18.52 13.25 16.28 15.10 16.20 15.96 14.70 15.69 18.04 13.53
PGF2a Ethanolamide
0.08 0.07 0.07 0.06 0.05 0.13 0.14 0.12 0.11 0.11 0.07 0.06 0.08 0.09 0.09
Stearoyl Ethanolamide
17.94 14.95 23.05 22.68 29.82 44.73 29.89 30.30 25.85 32.38 32.44 29.64 27.94 43.40 33.30

Factors:

F1Treatment:Early ITT Infusion Study | Timepoint:0 mins
F2Treatment:Early ITT Infusion Study | Timepoint:10 mins
F3Treatment:Early ITT Infusion Study | Timepoint:120 mins
F4Treatment:Early ITT Infusion Study | Timepoint:30 mins
F5Treatment:Early ITT Infusion Study | Timepoint:60 mins
F6Treatment:GLP1/Late GTT | Timepoint:0 mins
F7Treatment:GLP1/Late GTT | Timepoint:10 mins
F8Treatment:GLP1/Late GTT | Timepoint:120 mins
F9Treatment:GLP1/Late GTT | Timepoint:30 mins
F10Treatment:GLP1/Late GTT | Timepoint:60 mins
F11Treatment:Late ITT Infusion Study | Timepoint:0 mins
F12Treatment:Late ITT Infusion Study | Timepoint:10 mins
F13Treatment:Late ITT Infusion Study | Timepoint:120 mins
F14Treatment:Late ITT Infusion Study | Timepoint:30 mins
F15Treatment:Late ITT Infusion Study | Timepoint:60 mins
  logo